Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
Heidelberg Pharma AG announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting. The meeting will be held in a virtual format from April 10 – 15, 2021.
Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
Heidelberg Pharma AG today published its financial results and annual report for fiscal year 2020 (01 December 2019 – 30 November 2020) and its outlook for 2021.
Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
Heidelberg Pharma AG today announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). dievini will provide the Company with up to EUR 30 million. The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma as well as dievini at a later date.
The financing commitment will enable Heidelberg Pharma to advance its business activities, in particular to conduct the clinical Phase I/IIa of the HDP-101 and to further develop the candidates HDP-102 und HDP-103. Based on the current planning, the Company’s cash reach is secured until mid-2022.
Heidelberg Pharma Expands Management Team
Heidelberg Pharma AG today announced the appointment of Dr. András Strassz as Chief Medical Officer and Dr. Mathias Locher as Chief Development Officer.
Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
Heidelberg Pharma AG today announced that new study results on the Antibody Targeted Amanitin Conjugate (ATAC) technology have been published in the journal Science Translational Medicine, in a joint report by a research group at the School of Medicine, Indiana University, Indianapolis, IN, USA, and scientists of Heidelberg Pharma.
Inside information pursuant to Article 17 MAR
FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Heidelberg Pharma AG today announced that the US Food and Drug Administration (FDA) has informed the company it is safe to proceed with the Phase I/IIa study with the BCMA Antibody Targeted Amanitin Conjugate, HDP-101 that was submitted under its US IND. The study will evaluate HDP- 101 for the treatment of multiple myeloma, a blood cancer with high unmet medical need.
Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Receives Shareholder Loan Based on an Existing Financing Commitment
Heidelberg Pharma AG today announced that it has signed a subordinated loan agreement for a total amount of EUR 15 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany. The amount of the loan corresponds to the financing commitment from 21 July 2020 that will secure the company’s cash reach until mid-2021.
Heidelberg Pharma will Present at German Equity Forum and Provides Update on Partner Activities for its Legacy Assets
Heidelberg Pharma AG today announced that it will give a presentation at the German Equity Forum (Eigenkapitalforum, EKF) and provided an update on recent news from its licensing partners.
Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020
Heidelberg Pharma AG today announced that it will present the design for the planned clinical trial with HDP-101 at the 62nd Annual Meeting of the American Society of Hematology (ASH). In addition, partners MD Anderson Cancer Center, Houston, TX, USA, (MD Anderson) and Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) will present data on the ATAC technology. The conference will take place from 5th to 8th December 2020 in a virtual format.
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2020
Heidelberg Pharma AG today reported on the first nine months of fiscal year 2020 (1 December 2019 – 31 August 2020) and the Group’s financial figures.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz